-dipyridamole

Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2012/05/25 12:55:22」(JST)

wiki en

[Wiki en表示]

Dipyridamole (trade name Persantine) is a drug that inhibits thrombus formation^[1] when given chronically and causes vasodilation when given at high doses over a short time.

Mechanism and effects

It acts as a thromboxane synthase inhibitor, therefore lowering the levels of TXA2 and thus stops the effects of TXA2 (platelet aggregation, bronchioconstriction and vasoconstriction).
It inhibits the cellular reuptake of adenosine into platelets, red blood cells and endothelial cells leading to increased extracellular concentrations of adenosine.
It also inhibits the enzyme adenosine deaminase, which normally breaks down adenosine into inosine. This inhibition leads to further increased levels of extracellular adenosine.
Dipyridamole also inhibits the phosphodiesterase enzymes that normally break down cAMP (increasing cellular cAMP levels and blocking the platelet response to ADP) and/or cGMP (resulting in added benefit when given together with NO or statins).

Medical uses

Dipyridamole has been shown to lower pulmonary hypertension without significant drop of systemic blood pressure
It inhibits formation of pro-inflammatory cytokines (MCP-1, MMP-9) in vitro and results in reduction of hsCRP in patients.
It inhibits proliferation of smooth muscle cells in vivo and has shown to prevent AV-shunt failure in dialysis patients.
It increases the release of t-PA from brain microvascular endothelial cells
It results in an increase of 13 - HODE and decrease of 12 - HETE in the subendothelial matrix (SEM) and reduced thrombogenicity of the SEM.
Pretreatment it reduced reperfusion injury in volunteers.
It has been shown to increase myocardial perfusion and left ventricular function in patients with ischemic cardiomyopathy.
It results in a reduction of the number of thrombin and PECAM-1 receptors on platelets in stroke patients.
cAMP impairs platelet aggregation and also causes arteriolar smooth muscle relaxation. Chronic therapy did not show significant drop of systemic blood pressure.
It inhibits the replication of mengovirus RNA.^[2]
It can be used for myocardial stress testing as an alternative to exercise-induced stress methods such as treadmills.

Use in individuals with a history of stroke

Modified release dipyridamole is used in conjunction with aspirin (under the trade names Aggrenox in the USA or Asasantin Retard in the UK) in the secondary prevention of stroke and transient ischaemic attack. This practice has been confirmed by the ESPRIT trial.^[3] Dipyridamole absorption is pH-dependent and concomitant treatment with gastric acid suppressors (such as a proton pump inhibitor) will inhibit the absorption of liquid & plain tablets.^[4]^[5] Modified release preparations are buffered and absorption is not affected.^[6]^[7]

It is not, however, licensed as monotherapy for stroke prophylaxis, although a Cochrane Review has suggested that dipyridamole may reduce the risk of further vascular events in patients presenting after cerebral ischaemia.^[8]

A triple therapy of aspirin, clopidogrel and dipyridamole has been investigated, but this combination led to an increase in adverse bleeding events.^[9]

Via the mechanisms mentioned above, when given as 3 to 5 min infusion it rapidly increases the local concentration of adenosine in the coronary circulation which causes vasodilation.
Vasodilation occurs in healthy arteries, whereas stenosed arteries remain narrowed. This creates a "steal" phenomenon where the coronary blood supply will increase to the dilated healthy vessels compared to the stenosed arteries which can then be detected by clinical symptoms of chest pain, electrocardiogram and echocardiography when it causes ischemia.
Flow heterogeneity (a necessary precursor to ischemia) can be detected with gamma cameras and SPECT using nuclear imaging agents such as Thallium-201 and Tc99m-Sestamibi. However relative differences in perfusion not necessarily imply absolute decrease in blood supply in the tissue supplied by a stenosed artery.

Other uses

Dipyridamole also has non-medicinal uses in a laboratory context, such as the inhibition of cardiovirus growth in cell culture.

Overdose

Dipyridamole overdose can be treated with aminophylline^[10] and reverses its hemodynamic effects (vasodilation). Symptomatic treatment is recommended, possibly including a vasopressor drug. Gastric lavage should be considered. Administration of xanthine derivatives (e.g., aminophylline) may reverse the hemodynamic effects of dipyridamole overdose. Since dipyridamole is highly protein bound, dialysis is not likely to be of benefit.

References

^ "Dipyridamole" at Dorland's Medical Dictionary
^ Dipyridamole in the laboratory: Fata-Hartley, Cori L.; Ann C. Palmenberg. "Dipyridamole reversibly inhibits mengovirus RNA replication". doi:10.1128/JVI.79.17.11062-11070.2005. http://jvi.asm.org/cgi/content/full/79/17/11062?view=long&pmid=16103157. Retrieved 2007-02-13.
^ Halkes PH, van Gijn J, Kappelle LJ, Koudstaal PJ, Algra A (May 2006). "Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial". Lancet 367 (9523): 1665–73. doi:10.1016/S0140-6736(06)68734-5. PMID 16714187. http://linkinghub.elsevier.com/retrieve/pii/S0140-6736(06)68734-5.
^ Russell TL, Berardi RR, Barnett JL, O’Sullivan TL, Wagner JG, Dressman JB. pH-related changes in the absorption of "dipyridamole" in the elderly. Pharm Res (1994) 11 136–43.
^ Derendorf H, VanderMaelen CP, Brickl R-S, MacGregor TR, Eisert W. "Dipyridamole" bioavailability in subjects with reduced gastric acidity. J Clin Pharmacol (2005) 45, 845–50.
^ http://emc.medicines.org.uk/medicine/304/SPC/Persantin+Retard+200mg/#EXCIPIENTS
^ Stockley, Ivan (2009). Stockley’s Drug Interactions. The Pharmaceutical Press. ISBN 0-85369-424-9.
^ De Schryver ELLM, Algra A, van Gijn J. (2007). Algra, Ale. ed. "Dipyridamole for preventing stroke and other vascular events in patients with vascular disease.". Cochrane Database of Systematic Reviews 2007 (2): CD001820. doi:10.1002/14651858.CD001820.pub3. PMID 17636684. http://www.cochrane.org/reviews/en/ab001820.html.
^ Sprigg N, Gray LJ, England T, et al. (2008). Berger, Jeffrey S.. ed. "A randomised controlled trial of triple antiplatelet therapy (aspirin, clopidogrel and dipyridamole) in the secondary prevention of stroke: safety, tolerability and feasibility". PLoS ONE 3 (8): e2852. doi:10.1371/journal.pone.0002852. PMC 2481397. PMID 18682741. http://www.plosone.org/article/info:doi/10.1371/journal.pone.0002852.
^ Aggrenox. RxList.com. URL: http://www.rxlist.com/cgi/generic/aggrenox_od.htm. Accessed on: May 1, 2007.

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 血管拡張剤負荷による放射性核種心筋血流イメージング：検査方法と安全性 vasodilator stress radionuclide myocardial perfusion imaging testing methodologies and safety
2. 脳卒中の二次予防のための抗血小板療法 antiplatelet therapy for secondary prevention of stroke
3. 冠動脈疾患の予後および診断における血管拡張剤負荷による放射性核種心筋血流イメージング vasodilator stress radionuclide myocardial perfusion imaging in the diagnosis and prognosis of coronary heart disease
4. 治療を受けた非ST上昇型急性冠症候群患者の退院前の重症度分類における核種心筋血流イメージング radionuclide myocardial perfusion imaging in predischarge risk stratification of medically treated patients with non st elevation acute coronary syndrome
5. 冠動脈疾患の診断および予後における負荷心エコー stress echocardiography in the diagnosis and prognosis of coronary heart disease

English Journal

DNA methylation detection by a novel fluorimetric nanobiosensor for early cancer diagnosis.

Dadmehr M1, Hosseini M2, Hosseinkhani S3, Ganjali MR4, Khoobi M5, Behzadi H6, Hamedani M7, Sheikhnejad R7.
Biosensors & bioelectronics.Biosens Bioelectron.2014 Oct 15;60:35-44. doi: 10.1016/j.bios.2014.03.033. Epub 2014 Apr 15.
A very sensitive and convenient fluorescence nanobiosensor for rapid detection of DNA methylation based on Fe3O4/Au core/shell nanoparticles has been developed. Specific site of CpG islands of adenomatous polyposis coli (APC), a well studied tumor suppressor gene, was used as the detection target DN
PMID 24768860

In vivo predictive mini-scale dissolution for weak bases: Advantages of pH-shift in combination with an absorptive compartment.

Frank KJ1, Locher K1, Zecevic DE1, Fleth J2, Wagner KG3.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.Eur J Pharm Sci.2014 Sep 30;61:32-9. doi: 10.1016/j.ejps.2013.12.015. Epub 2014 Jan 8.
The purpose was the evaluation of a new miniscale biphasic dissolution model with pH-shift (miBIdi-pH). Its capability to predict supersaturation and precipitation of weak bases (e.g. dipyridamole) and the in vivo performance of various formulations of the model compound BIXX (weak base, poor solubi
PMID 24413061

Synthesis, characterization and mechanistic-insight into the anti-proliferative potential of PLGA-gemcitabine conjugate.

Khare V1, Kour S2, Alam N1, Dubey RD1, Saneja A3, Koul M2, Gupta AP4, Singh D5, Singh SK6, Saxena AK2, Gupta PN7.
International journal of pharmaceutics.Int J Pharm.2014 Aug 15;470(1-2):51-62. doi: 10.1016/j.ijpharm.2014.05.005. Epub 2014 May 6.
Gemcitabine, a nucleoside analogue, is used in the treatment of various solid tumors, however, its efficacy is limited by rapid metabolism by cytidine deaminase and fast kidney excretion. In this study, a polymeric conjugate of gemcitabine was prepared by covalent coupling with poly(lactic-co-glycol
PMID 24810239

Japanese Journal

負荷Tl-201心筋SPECTにおける一過性左室拡大の規定因子:運動負荷とジピリダモール負荷の比較

増渕充世/近藤千里/萩原誠久
東京女子医科大学雑誌 82(1), 23-29, 2012-02-25
【緒言】負荷心筋SPECTにおける一過性虚血性左室拡大 (TID: transient ischemic dilation of the left ventricle)は、多枝病変や、左冠動脈主幹部狭窄などの重症冠動脈病変に関連する所見と考えられている。しかし、我々は、ジピリダモール負荷タリウム心筋SPECTにおいて、重症冠動脈疾患を有している可能性が極めて低いと思われる症例でも、TIDを臨床的に …
NAID 110008802811

多項目自動血球分析装置XE-5000を用いた幼若血小板比率(IPF%)測定における抗凝固剤と保存温度の影響 : 抗凝固剤CTADと室温保存の有用性

西山美保,林悟,兜森修,山西八郎,末久悦次,倉田義之,柏木浩和,冨山佳昭
臨床病理 59(5), 452-458, 2011-05-25
NAID 10029427358

Related Pictures

★リンクテーブル★

リンク元	「抗狭心症薬」「ジピリダモール」
拡張検索	「dipyridamole myocardial perfusion scintigraphy」「dipyridamole stress」

「抗狭心症薬」

Dipyridamole
	Classification and external resources
ICD-10	T46.3
ICD-9	972.4

Dipyridamole
Systematic (IUPAC) name
	2,2',2'',2'''-(4,8-di(piperidin-1-yl)pyrimido[5,4-d]pyrimidine-2,6-diyl)bis(azanetriyl)tetraethanol
Clinical data
Trade names	Persantine
AHFS/Drugs.com	monograph
MedlinePlus	a682830
Pregnancy cat.	B
Legal status	?
Routes	PO, IV
Pharmacokinetic data
Protein binding	99%
Metabolism	Hepatic
Half-life	Alpha (40 mins), Beta (10 Hours)
Identifiers
CAS number	58-32-2
ATC code	B01AC07
PubChem	CID 3108
DrugBank	DB00975
ChemSpider	2997
UNII	64ALC7F90C
KEGG	D00302
ChEBI	CHEBI:4653
ChEMBL	CHEMBL932
Chemical data
Formula	C24H40N8O4
Mol. mass	504.626 g/mol
SMILES	eMolecules & PubChem
	InChI InChI=1S/C24H40N8O4/c33-15-11-31(12-16-34)23-26-20-19(21(27-23)29-7-3-1-4-8-29)25-24(32(13-17-35)14-18-36)28-22(20)30-9-5-2-6-10-30/h33-36H,1-18H2 ; Key:IZEKFCXSFNUWAM-UHFFFAOYSA-N ;
(what is this?) (verify);

　　[★]

英: antianginal agents, antianginal drug
関: 狭心症

種類

硝酸薬

冠血管スパズム緩解→酸素供給↑
末梢血管拡張→心筋仕事量↓→心筋酸素需要↓

特徴

小動脈より静脈を拡張させる　→　前負荷の減少
冠血管では、細い動脈より太い動脈を弛緩させる

β遮断薬

心筋抑制→心筋仕事量↓→心筋酸素需要↓

Ca拮抗薬

冠血管スパズム緩解→酸素供給↑ (SPC.226)
心筋抑制→心筋仕事量↓→心筋酸素需要↓

作用機序

電位依存性型Ca²⁺チャネルのαサブユニットに作用

その他の冠血管拡張薬